Halozyme Therapeutics (LTS:0J2O) Beginning Cash Position : $118.4 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Halozyme Therapeutics Beginning Cash Position?

Halozyme Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was $118.4 Mil.

Halozyme Therapeutics's quarterly Beginning Cash Position increased from Sep. 2023 ($221.2 Mil) to Dec. 2023 ($274.2 Mil) but then declined from Dec. 2023 ($274.2 Mil) to Mar. 2024 ($118.4 Mil).

Halozyme Therapeutics's annual Beginning Cash Position declined from Dec. 2021 ($148.2 Mil) to Dec. 2022 ($119.2 Mil) but then increased from Dec. 2022 ($119.2 Mil) to Dec. 2023 ($234.7 Mil).

Halozyme Therapeutics Beginning Cash Position Historical Data

The historical data trend for Halozyme Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Beginning Cash Position Chart

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

58.44

120.68

148.20

119.22

234.70

Halozyme Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															234.70	96.88	221.17	274.23	118.37

Halozyme Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Halozyme Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (LTS:0J2O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (LTS:0J2O) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

HALO:USA RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics (LTS:0J2O) Headlines

No Headlines